Latest News and Press Releases
Want to stay updated on the latest news?
-
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Immuneering Corporation Announces Grant of Inducement Award
-
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
-
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
-
Immuneering Launches Pancreatic Cancer Advisory Board
-
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
-
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
-
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Immuneering to Present at the Jefferies Global Healthcare Conference
-
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...